Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.

Cancer medicine - 1 Sept 2024

Terán Eduardo, Lozano Rebeca, Rodríguez César A, Abad Mar, Figuero Luis, Muñoz José Antonio, Cigarral Belén, Rodrígues Aline, Sancho Magdalena, Gómez M Asunción, Morchón Daniel, Montero Juan Carlos, Sayagués José María, Ludeña M Dolores, Fonseca Emilio

Abstract excerpt

INTRODUCTION: Hotspots (HS) mutations in the PIK3CA gene may lead to poorer oncological outcomes and endocrine resistance in advanced breast cancer (BC), but their prognostic role in early-stage disease remains controversial. The overall agreement within plasma and tissue methods has not been well explored. Our aim was to correlate tissue and plasma approaches and to analyze the prognostic impact of PIK3CA...

Topics

Join the communities discussing this publication.

Aged, 80 and over
Biomarkers, Tumor
Breast Neoplasms
Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptor, ErbB-2

Receptors, Estrogen

Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 39235099
DOI: 10.1002/cam4.70101
PMCID: PMC11375731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.PMID 39235099Read ↗

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.Semantic proximity Read ↗

PIK 3 CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison studySemantic proximity Read ↗

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast CancerSemantic proximity Read ↗

PIK3CA mutations in breast cancerSemantic proximity Read ↗

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.Semantic proximity Read ↗

PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Semantic proximity Read ↗

PIK3CA-mutations in breast cancer.Semantic proximity Read ↗

The Diagnostic Accuracy of PIK3CA Mutations by circulating tumor DNA (ctDNA) in Breast Cancer: An Individual Patient Data Meta-analysisSemantic proximity Read ↗

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.Semantic proximity Read ↗

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.